Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Abstract Acute myeloid leukaemia (AML) is a highly aggressive and devastating malignancy of the bone marrow and blood. For decades, intensive chemotherapy has been the frontline treatment for AML but has yielded only poor patient outcomes as exemplified by a 5-year survival rate of < 30%, even in yo...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Nature Publishing Group
2024-06-01
|
| Sraith: | Cell Death and Disease |
| Rochtain ar líne: | https://doi.org/10.1038/s41419-024-06810-7 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|